Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash Flows From Operating Activities
Net loss	$ (48,850,138)	$ (27,977,976)
Adjustments to reconcile net loss to cash flows (used in) provided by operating activities
Depreciation expense	10,486,335	9,420,585
Amortization of note discounts	3,157,815	3,610,738
Amortization of financing liability	5,146,586
Recognition and impairment of film costs	1,305,000
Interest income on investments held to maturity	(563,652)
Interest paid in kind	4,334,790	2,659,044
Loss on extinguishment of debt		148,472
Gain on sale of asset	(148,796)
Change in fair value of interest rate swap	(163,850)	128,000
Change in fair value of warrant liability	(507,000)	(9,011,000)
Change in fair value of investments available for sale	(1,683,246)
Stock-based compensation expense	2,520,210	3,277,879
Non-cash operating lease expense	390,502	134,111
Changes in operating assets and liabilities:
Accounts receivable	(1,935,867)	(1,201,990)
Prepaid expenses and other assets	(124,927)	719,172
Accounts payable and accrued expenses	5,838,427	16,092,721
Operating leases	(240,234)	13,436
Due to affiliates	396,876	2,740,818
Other liabilities	1,034,870	1,659,949
Net cash (used in) provided by operating activities	(19,606,299)	2,413,959
Cash Flows From Investing Activities
Investments in securities held to maturity	(71,947,597)
Proceeds from securities held to maturity	89,470,392
Proceeds from sale of property and equipment	241,691
Additions to project development costs and property and equipment	(37,833,640)	(77,862,339)
Net cash used in investing activities	(20,069,154)	(77,862,339)
Cash Flows From Financing Activities
Proceeds from notes payable	24,270,339	68,807,100
Repayments of notes payable	(1,069,800)	(8,238,479)
Payment of financing costs	(1,554,048)	(5,447,177)
Payment on financing lease	(3,281,250)
Payment of Series B dividends	(450,000)	(450,000)
Payment for repurchase of interest rate swap	(36,150)
Proceeds from failed sale leaseback		15,588,519
Proceeds from sale of common stock under ATM	39,261	20,403,517
Net cash provided by financing activities	17,918,352	90,663,480
Net (decrease) increase in cash and restricted cash	(21,757,101)	15,215,100
Cash and restricted cash, beginning of year	33,516,382	17,388,040
Cash and restricted cash, end of period	11,759,281	32,603,140
Cash	4,307,380	15,913,191
Restricted Cash	7,451,901	16,689,949
Total cash and restricted cash	11,759,281	32,603,140
Supplemental disclosure of cash flow information
Cash paid during the year for interest	6,553,721	4,466,500
Cash paid for income taxes
Non-cash investing and financing activities
Project development cost acquired through accounts payable and accrued expenses, net		334,658
Amendment of Series C warrant liability for equity classification		3,336,000
Amendment of Series C and D warrants		400,000
Initial value of right of use asset upon adoption of ASC 842		7,741,955
Accrued Series B preferred stock dividends	348,000	348,000
Shares issued in connection with amendment of notes payable		803,061
Warrants issued in connection with amendment of notes payable		1,088,515
Amounts due to affiliate exchanged for notes payable		850,000
Shares issued in connection with issuance of notes payable		75,419
Warrants issued in connection with issuance of notes payable		$ 18,709